Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1053/j.ajkd.2011.09.005 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Association Between Early Immunosuppression Center Variability and One-Year Outcomes After Pediatric Liver Transplant.
Pediatr Transplant
February 2025
Division of Pediatric Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, University of California San Francisco, San Francisco, California, USA.
Background: Despite the existence of institutional protocols, liver transplant centers often have variability in early immunosuppression practices. We aimed to measure within-center variability in early immunosuppression after pediatric liver transplant (LT) and examine its association with one-year outcomes.
Methods: We analyzed pediatric LTs from 2013 to 2018 in the United Network for Organ Sharing registry, with data aggregated by center.
Safety and Efficacy of Glofitamab for Relapsed/Refractory Large B-Cell Lymphoma in a Multinational Real-World Study.
Blood Adv
December 2024
Charité, University Medical Center Berlin, Campus Benjamin Franklin, Berlin, Germany.
Article Synopsis
- Glofitamab, a bispecific antibody targeting CD20 and CD3, shows promise for treating relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL) in heavily pretreated patients, with an overall response rate of 47%.
- In a study involving 70 patients in Germany, Austria, and Switzerland, the median number of prior treatments was four, with notable safety concerns including cytokine release syndrome in 40% of cases.
- Important findings indicate that elevated LDH levels predict poorer outcomes, and recent treatment with bendamustine may reduce the efficacy of glofitamab, suggesting careful treatment sequencing is essential.
ATG-Thymoglobulin Versus ATG-Fresenius for Conditioning in Thalassemia Patients Who Underwent Allogenic Stem Cell Transplantation from Matched-Sibling Donor: A Tertiary Cancer Care Center Short-Term Experience.
Hemoglobin
May 2024
Department of Hematology and Bone Marrow Transplant Unit, Rajiv Gandhi Cancer Institute and Research Centre, Delhi, India.
Graft rejection and Graft-versus-host disease (GVHD) are some of the significant factors resulting in morbidity and mortality following allogeneic hematopoietic cell transplantation. Prophylaxis for GVHD using T-cell depleting agents is helpful in reducing the transplant-related mortality and graft rejection. Both tATG and fATG exhibit varied amounts of antibody specificities and perform distinct immunomodulatory effects, regardless of their capacity to deplete T-lymphocytes.
View Article and Find Full Text PDFBridging the gap: assessing CMV DNAemia in kidney transplant recipients with previous solid organ transplants.
Front Transplant
April 2024
Department of Pharmacy, Duke University Hospital, Durham, NC, United States.
Cytomegalovirus (CMV) infection poses a significant threat to solid organ transplant (SOT) recipients and can lead to various complications and adverse outcomes. In an effort to prevent CMV infection, it is common to utilize prophylactic strategies, including antiviral medications such as valganciclovir, especially for high-risk patients. Risk factors for CMV infection in kidney transplant recipients (KTRs) include CMV mismatch between donor and recipient (i.
View Article and Find Full Text PDFPost-transplant lymphoproliferative disorders following kidney transplantation: A literature review with updates on risk factors, prognostic indices, screening strategies, treatment and analysis of donor type.
Transplant Rev (Orlando)
April 2024
Hammersmith Hospital, Imperial College Healthcare NHS Trust, Department of Transplant and General Surgery, London, United Kingdom. Electronic address:
Post-transplant lymphoproliferative disorders (PTLD) is a devastating complication of kidney transplantation with an insidious presentation and potential to disseminate aggressively. This review delineates the risk factors, prognostic indexes, screening, current management algorithm and promising treatment strategies for PTLD. Kidneys from both extended criteria donors (ECD) and living donors (LD) are being increasingly used to expand the donor pool.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!